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Charcot-Marie-Tooth (CMT) disease represents a clinically and genetically heterogeneous group of inherited neuropathies. Here, we
report a five-generation family of eight affected individuals with CMT disease type 2, CMT2. Genome-wide linkage analysis showed
that the disease phenotype is closely linked to chromosomal region 10p13-14, which spans 5.41 Mb between D10S585 and
D10S1477. DNA-sequencing analysis revealed a nonsense mutation, c.1455T>G (p.Tyr485*), in exon 8 of dehydrogenase E1 and trans-
ketolase domain-containing 1 (DHTKD1) in all eight affected individuals, but not in other unaffected individuals in this family or in
250 unrelated normal persons. DHTKD1 mRNA expression levels in peripheral blood of affected persons were observed to be half of
those in unaffected individuals. In vitro studies have shown that, compared to wild-type mRNA and DHTKD1, mutant mRNA and trun-
cated DHTKD1 are significantly decreased by rapid mRNA decay in transfected cells. Inhibition of nonsense-mediated mRNA decay by
UPF1 silencing effectively rescued the decreased levels of mutantmRNA and protein. More importantly,DHTKD1 silencing was found to
lead to impaired energy production, evidenced by decreased ATP, total NADþ and NADH, and NADH levels. In conclusion, our data
demonstrate that the heterozygous nonsense mutation in DHTKD1 is one of CMT2-causative genetic alterations, implicating an impor-
tant role for DHTKD1 in mitochondrial energy production and neurological development.Charcot-Marie-Tooth (CMT) disease is one of the most
common inherited neurological disorders.1,2 Individuals
with CMT experience symmetric, slowly progressive distal
motor neuropathy of the arms and legs; this usually begins
in the first to third decade of life and results in weakness
and atrophy of the muscles in the feet and/or hands. Clin-
ically, CMT can be divided into two major phenotypic
types: a demyelinating form (CMT disease type 1) affecting
the glia-derived myelin and an axonal form (CMT disease
type 2 [CMT2]) affecting the nerve axon.3,4 Genetically,
mutant alleles underlying CMT can segregate in an auto-
somal-dominant, recessive, or X-linked manner involving
43 unique genes.5,6 The overall prevalence of CMT is esti-
mated at 1–5 in 10,000 individuals. CMT2 represents
25%–30% (1:10,000) of all CMT cases characterized by
distal muscle weakness and atrophy, mild sensory loss,
and normal or near-normal nerve conduction velocities.7
The median motor conduction velocity is above 38 m/s
(GeneReviews in Web Resources). Until now, mutations
in 15 unique genes have been identified as causing
CMT28–10 (also see GeneReviews in Web Resources). All
these subtypes of CMT2 are similar clinically and are
distinguished mainly by molecular-genetic findings.
More importantly, the genetic mutations in most CMT2-
associated genes have been found to lead to defects in
mitochondrial function or axonal transport, the most
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ment of mitochondrial function has been put forward as
a general critical component of the disease mechanisms
in hereditary neuropathies because the defects in mito-
chondrial function or axonal transport could dramatically
affect the peripheral nerves by depriving the distal axon of
a needed source of energy.11,12
In the present work, we report a five-generation family
(from the Shandong Province of China) affected by auto-
somal-dominant CMT2. This family was ascertained
through initial identification of the proband (IV-25 in
Figure 1A). The study was approved by the committee of
Basic Medicine Faculty at Shanghai Jiao Tong University
School of Medicine. After informed consent was obtained,
all family members who agreed to participate in this study
were evaluated by experienced neurologists. All affected
individuals (five males and three females) presented with
certain typical CMT2 phenotypes, including symmetrical
muscle wasting and a predominating weakness of the
distal parts of the lower limbs, decreased or absent deep-
tendon reflexes, and mild to moderate deep sensory
impairment. The clinical records and CMT neuropathy
scores of all affected individuals are shown in Table S1,13
available online. For confirmation of the diagnosis, the
proband was carefully examined in Rui-Jin Hospital. The
initial complaints of the proband included difficulty
walking and tripping due to foot and distal leg weaknessics, E-Institutes of Shanghai Universities, Shanghai Jiao Tong University
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Figure 1. A Chinese Family Affected by Autosomal-Dominant CMT2
(A) CMT2 pedigree. The arrow marks the proband (IV-25) with CMT2 in this pedigree.
(B and C) Distal upper- and lower-limb muscle atrophies in IV-25.
(D) Muscle-biopsy section of the proband shows some angulated muscle fibers, and increased connective and fat tissues around the
muscle bundle in hematoxylin and eosin staining. The scale bar represents 100 mm.
(E) Electron microscopy reveals mitochondrial vacuolization in muscle cells. The scale bar represents 5,000 nm.at the age of 15 years. Neurological examination revealed
muscle atrophy in the distal parts of forearm and inteross-
eous muscles of the hands (Figure 1B). His lower legs
developed severe muscle atrophy, which presented as
‘‘crane-leg-like’’ malformations (Figure 1C). On electro-
physiological examination, both motor-nerve conduction
velocities (MNCVs) and sensory-nerve conduction veloci-
ties (SNCVs) were normal (>52.4 m/s) in the upper limbs.
In his lower limbs, MNCVs seemed to be reduced (38.9–
40.4 m/s), but SNCVs were normal (>46.4 m/s). Such fluc-
tuation in MNCVs in the proband seems, to some degree,
to reflect the heterogeneity in neuropathological alteration
of CMT2. The compound motor action potentials were
reduced in amplitude in his upper and lower limbs. For
histological analysis, a muscle sample was taken from the
biceps brachii muscle of individual IV-25. Some small, an-
gulated muscle fibers were found with the use of hematox-The American Jouylin and eosin staining (Figure 1D). Electron microscopy
showed sarcomere disappearance, disorganized myofila-
ments, and mitochondrial vacuolization in muscle cells
(Figure 1E). These electrophysiological and morphological
findings are characteristic of an axonal CMT phenotype.
Considering the genetic heterogeneity of CMT2, we
directly performed a genome-wide scan by using 401
markers that cover the human genome at 10 cM average
resolution. The results showed no linkage to any known
loci for CMT2 (Table S2). However, we were able to identify
in chromosomal region 10p13-14 a single locus that cose-
gregated with the disease (Table S3). Further genotype and
haplotype analyses (Figure S1) narrowed the linkage region
to a 5.41 Mb interval between markers D10S585 and
D10S1477 (maximum two-point LOD score ¼ 4.56 at q ¼
0.0 at D10S506). This genetic interval encompasses 20
candidate genes (Figure S2). To find the disease-associatedrnal of Human Genetics 91, 1088–1094, December 7, 2012 1089
Figure 2. Identification of the c.1455T>G Mutation in Exon 8 of DHTKD1
(A) Physical map of the region between genetic markers D10S585 and D10S1477. The red line indicates DHTKD1. The black lines show
the physical distances (upper) and genetic markers (lower). This map is based on a human genomic sequence (RefSeq NM_018706.5).
(B) Illustration of the exon-intron structure of DHTKD1. The exons marked as blue boxes are numbered as exons 1–17 (upper), and the
coding region and amino acids 1–919 are labeled below. The point mutation of DHTKD1 is marked as a red line in exon 8.
(C) BLASTcomparison of the sequence from amino acids 470–501 in orthologs of DHTKD1 among species. The red arrow and characters
indicate the amino acid highly conserved among species in which p.Tyr485* was identified.
(D) Sequence chromatograms of theDHTKD1mutation. Left and right diagrams show normal andmutated sequences, respectively. The
mutation site (T>G) is indicated (arrows).
(E and F) Computer simulation of DHTKD1 structure with PyMOL-1 software. The cartoon structures of wild-type (E) and truncated (F)
DHTKD1 show that a probable pyrimidine-binding domain of thiamine-pyrophosphate-dependent enzymes is missing as a result of the
p.Tyr485* alteration.gene, we first considered phytanoyl-CoA hydroxylase
(PHYH [MIM 602026]), located in chromosomal region
10p13. The gene was previously reported to be associated
with hereditary motor and sensory neuropathy IV
(HSMN4 [MIM 266500]) with autosomal-recessive inheri-
tance.14 Sequencing analysis of PHYH (RefSeq accession
number NM_006214.3) revealed an identical wild-type
sequence in affected individuals and control subjects.
Therefore, PHYH was ruled out as a candidate gene in
this pedigree. We further selected 19 other candidate genes
within this region for sequencing analysis. Among these
candidate genes screened, we finally identified a nonsense
mutation, c.1455T>G (p.Tyr485*), in exon 8 of dehydroge-
nase E1 and transketolase domain-containing 1 (DHTKD1
[RefSeq NM_018706.5]) in only eight affected individuals
of this family. Such genetic mutation was not detected in
unaffected members in the family or in 250 unrelated,
ethnically matched individuals (i.e., 500 chromosomes).
We also checked DHTKD1 sequence information in the
database of the 1000 Genomes Project. No such variation
(c.1455T>G) in DHTKD1 was found. To confirm the1090 The American Journal of Human Genetics 91, 1088–1094, Deceinvolvement of DHTKD1 in CMT2, we screened ten unre-
lated CMT2-affected individuals from eight independent
pedigrees for the mutations in DHTKD1. However,
no mutations were observed in these affected individ-
uals. These data suggest that the DHTKD1 mutation
(c.1455T>G) is a disease-associated genetic variation cose-
gregating with the CMT2 phenotype in this family.
DHTKD1 is presumed to be a nuclear-encoded mito-
chondrial precursor protein, also named ‘‘probable 2-
oxoglutarate dehydrogenase E1 component DHTKD1.’’
Its physiological function remains largely unknown to
date.15 DHTKD1 is localized in chromosomal region
10p14, which is between D10S585 and D10S1705
(Figure 2A). There are 17 exons with an open reading frame
of 5,202 bp, encoding a peptide of 919 amino acids (Fig-
ure 2B).16 BLAST comparison of the sequence from amino
acids 470–501 in orthologs of DHTKD1 among species
revealed that the amino acids from 483 to 485 are
highly conserved except in Drosophila melanogaster and
Caenorhabditis elegans (Figure 2C). The T to G transition
at nucleotide position 1,455 presumably causes an aminomber 7, 2012
Figure 3. Mutant DHTKD1 mRNA Is Degraded via NMD
(A) DHTKD1mRNA detected by quantitative PCR (qPCR) in peripheral blood from the affected individuals and unaffected persons (six
each) is normalized against GAPDH (glyceraldehyde-3-phosphate dehydrogenase [MIM 138400]). One of three independent experi-
ments in triplicate is shown. A Student’s two-sided t test was used for comparing values of test and control samples. **p < 0.01.
(B) HEK 293T cells transfected with 2 mg of plasmid DNA of wild-type and mutant EGFP-DHTKD1 expression vectors under the same
conditions show that the mutant construct exhibits a lower fluorescence yield.
(C) Total cell lysates of HEK 293T cells transfected with wild-type and mutant EGFP-DHTKD1 vectors were assayed by immunoblotting
with either DHTKD1 or EGFP antibodies.
(D) HEK 293T cells were transfected, and total RNA was extracted at the indicated times. The mRNA expression levels detected by qPCR
are shown.
(E) ThemRNA stability was evaluated 24 hr after transfection in the presence of actinomycin D. Total RNAwas extracted at the indicated
time, and the mRNA levels were assayed by qPCR.
(F) Effective inhibition of UPF1 in HEK 293T cells by RNA interference resulted in increased mRNA of EGFP-DHTKD1 harboring the
c.1455T>G mutation, assayed by qPCR. Significant differences were observed between UPF1 silencing and the control. One of three
independent experiments in triplicate is shown in (D), (E), and (F). *p < 0.05, **p < 0.01, ***p < 0.001.
(G) HEK 293T cells were sequentially transfected with UPF1 siRNA and wild-type or mutant EGFP-DHTKD1 expressing vectors. The
protein levels of UPF1 and wild-type DHTKD1 or its mutant form were detected with immunoblot analysis.acid change from tyrosine (TAT) to a stop codon (TAG) at
the 485th amino acid residue (Figures 2C and 2D). With
PyMOL software, computer simulation of the three-dimen-
sional structure of DHTKD1 revealed a truncated protein
missing the 435 C-terminal residues (Figures 2E and 2F).
To evaluate the effect of the mutant DHTKD1 expres-
sion, we tested mRNA expression levels in the peripheral
blood of six affected individuals and six unaffected familyThe American Joumembers by using quantitative RT-PCR. The results
showed that the abundance of DHTKD1mRNA in affected
persons was less than half of that in unaffected individuals
(3.055 1.72 versus 6.925 1.51, p< 0.01) (Figure 3A), sug-
gesting that DHTKD1 mRNA harboring the nonsense
mutation might be degraded through nonsense-mediated
mRNA decay (NMD). It is well known that the NMD
pathway can be triggered by mRNA harboring eitherrnal of Human Genetics 91, 1088–1094, December 7, 2012 1091
a frameshift or a nonsense mutation, and this can lead to
the rapid degradation of mutant mRNA and the protection
of cells from the production of nonfunctional or truncated
proteins with a dominant-negative effect.17 To address
whether the insufficient expression of mutant DHTKD1
is due to mRNA degradation via NMD, we transfected
wild-type and mutant enhanced-green-fluorescent-protein
(EGFP)-DHTKD1 expression vectors at the same dose into
human embryonic kidney (HEK) 293T cells. As expected,
the cells transfected with the mutant construct revealed
much weaker fluorescence signals than did those trans-
fected with the wild-type construct (Figure 3B). Under
the same experimental settings, total cell lysates were
prepared from transfected cells at different times posttrans-
fection. Immunoblot analysis using antibodies against
either DHTKD1 or EGFP showed a smaller, truncated
EGFP-fusion product (~83 kDa) with much lower protein
levels in mutant-construct-transfected cells than those in
the cells transfected with the wild-type construct, which
normally produces the full-length fusion protein
(~130 kDa) (Figure 3C). Accordingly, the mRNA tran-
scribed from the mutant construct was significantly
decreased (Figure 3D) and degraded more rapidly than
did the mRNA from the wild-type construct after actino-
mycin D treatment (Figure 3E). To confirm whether
mutant mRNA is degraded via NMD, we performed an
RNA-silencing experiment in HEK 293T cells; we aimed
to suppress the NMD pathway by using specific oligomers
against the core NMD factor UPF1 (UPF1 regulator of
nonsense transcripts homolog [MIM 601430]).18 The
results showed that UPF1 was effectively reduced to 1/3–
1/2 of the control at both mRNA and protein levels. As ex-
pected, decreased mutant mRNA and truncated protein
produced by the cotransfected mutant EGFP-DHTKD1
expression vector were rescued with downregulation of
UPF1 in a dose-dependent manner (Figures 3F and 3G).
Thus, we demonstrated that DHTKD1 mRNA harboring
the premature-translational-termination-codon mutation
is degraded through the NMD pathway and thus leads to
a considerably lower protein level of the truncated protein.
DHTKD1 was expressed ubiquitously in various tissues
and was proposed to localize to the mitochondria. Previ-
ously, a structure-function analysis showed that DHTKD1
probably catalyzes transformation of a physiologically rele-
vant structural analog of 2-oxoglutarate.15 It is known that
2-oxoglutarate is converted to succinyl-CoA and CO2 in
the presence of the 2-oxoglutarate-dehydrogenase
complex (also known as the alpha-ketoglutarate dehydro-
genase complex), which is composed of 2-oxoglutarate
dehydrogenase (OGDH, E1 [MIM 613022]), dihydrolipoa-
mide succinyltransferase (DLST, E2 [MIM 126063]), and
lipoamide dehydrogenase (DLDH, E3 [MIM 238331]).19
DHTKD1 and OGDHL, oxoglutarate-dehydrogenase-like,
were presumed to be similar to 2-oxoglutarate dehydroge-
nase (EC 1.1.4.2).15 Thus, it is reasonable to postulate that
DHTKD1 functions as a 2-oxoglutarate-dehydrogenase E1
component and plays an important role in energy produc-1092 The American Journal of Human Genetics 91, 1088–1094, Decetion in mitochondria through the tricarboxylic-acid cycle.
To address whether DHTKD1 plays a role in energy produc-
tion in mitochondria, we checked the cellular localization
of endogenous DHTKD1 stained with a specific antibody
in the HepG2 cell line. MitoTracker-Red dye was used as
a mitochondrial probe. As expected, endogenous DHTKD1
showed typically cytoplamic localization and colocalized
with mitochondria (Figure S3). We then designed three
siRNA oligomers against DHTKD1. The HEK 293T cells
transfected with these three oligomers showed an effective
silencing of endogenous DHTKD1 at both mRNA and
protein expression levels (Figure S4). Finally, we performed
an NADþ/NADH colorimetric assay for the energy transfor-
mation and redox state in HEK 293T cells,20 in which
DHTKD1 was effectively silenced with a DHTKD1 siRNA
mixture containing a molecular ratio equivalent to that
of three DHTKD1 siRNAs (Figures 4A and 4B). It was found
that the levels of ATP (Figure 4C), total NADþ and NADH
(Figure 4D), and NADH (Figure 4E) were significantly
decreased and accordingly increased the ratio of NADþ/
NADH (Figure 4F) in DHTKD1-insufficient cells compared
to controls (p < 0.05). These data indicate that DHTKD1
is essential for energy production. In vitro deprivation of
DHTKD1 via RNA interference led to reduced production
of ATP, total NADþ and NADH, and NADH, suggesting
an essential role for DHTKD1 in normal mitochondrial
function and energy production.
Mitochondrial dysfunction is known to be involved in
various neurodegenerative diseases, including CMT2.
Several CMT2-associated genes, including MFN2 (MIM
608507) and GDAP1 (MIM 606598), have been identified
as nuclear-DNA-encoded mitochondrial proteins.8 Muta-
tions in MFN2 (Mitofusin 2) have been shown to lead to
the dispersal of mitochondria and reduced mitochondrial
mobility. The downregulation of MFN2 could decrease
glucose oxidation and reduce mitochondrial-membrane
potential and then lead to insufficient axonal transport
of mitochondria, presumably in the extended axons of
peripheral nerves.21,22 Ganglioside-induced differentia-
tion-associated protein 1 (GDAP1) encodes a protein
anchored to the mitochondrial outer membrane. Muta-
tions in GDAP1 were found to result in CMT disease type
2K (CMT2K [MIM 607831]) or CMT disease type 4A
(MIM 214400). Interestingly enough, GDAP1 mutations
in fibroblasts from CMT2K-affected persons harbor-
ing a c.719G>A (p.Cys240Tyr) mutation (RefSeq
NM_018972.2) are associated with a mitochondrial-
complex-I defect.23 Complex I deficiency leads to reduced
NADH oxidation and decreased electron transfer, causing
a sharp reduction in ATP synthesis. The lack of ATP could
reduce mitochondrial mobility, particularly in the distal
portions of neuronal axons.23 Insufficient mitochondrial
motility in the long axons might explain, at least in part,
why the distal portions of the peripheral nerves are princi-
pally affected in CMT disease involving GDAP1 muta-
tions.12 Similar to the mutations in MFN2 and GDAP1,
the DHTKD1 nonsense mutation identified in thismber 7, 2012
Figure 4. DHTKD1 Is Essential for Energy
Production in Mitochondria
(A and B) Endogenous DHTKD1 was effec-
tively inhibited by RNA interference in
HEK 293T cells, evidenced by the results
of qPCR (A) and immunoblot analysis
(B). a-tubulin was used as an internal
control for protein loading.
(C–E) Cells were collected 72 hr after
DHTKD1-siRNA transfection. The cell
lysates were assayed by an enzyme-linked
immunosorbent assay for ATP (C), total
NADþ and NADH (D), and NADH (E)
levels.
(F) The ratio of NADþ to NADH is shown.
One of three independent experiments
in triplicate is shown for each above.
*p < 0.05, **p < 0.01.pedigree leads to insufficient energy production and
dysfunction of peripheral nerves as a result of rapid
mRNA degradation via NMD.
In conclusion, our findings demonstrate that CMT2
can be caused by the nonsense mutation in DHTKD1,
implicating an essential role for DHTKD1 in energy
production, normal neurological function, and the normal
redox reaction in mitochondria.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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